Data gathered: August 2
AI Stock Analysis - Esperion Therapeutics (ESPR)
Analysis generated May 21, 2025. Powered by Chat GPT.
Esperion Therapeutics, Inc. is a pharmaceutical company headquartered in Ann Arbor, Michigan. The company specializes in developing and commercializing oral medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Their key product, Nexletol (bempedoic acid), has shown promise as a new lipid-lowering treatment, particularly for patients who inadequately respond to or cannot tolerate statins. Esperion aims to cater to the unmet need in cardiovascular disease management by providing alternative cholesterol-lowering therapies.
Stock Alerts - Esperion Therapeutics (ESPR)
 |
Esperion Therapeutics | July 29 Price is down by -7.2% in the last 24h. |
|
Esperion Therapeutics | July 28 Price is up by 8.3% in the last 24h. |
|
Esperion Therapeutics | July 24 Price is up by 7.1% in the last 24h. |
|
Esperion Therapeutics | July 23 Price is up by 7.4% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Esperion Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 15 | Sign up | Sign up | Sign up |
| Sentiment | 99 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 7 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 600 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 9,114 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,114 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | 2 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 56 | Sign up | Sign up | Sign up |
| Linkedin Employees | 344 | Sign up | Sign up | Sign up |
About Esperion Therapeutics
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
| Price | $1.40 |
| Target Price | Sign up |
| Volume | 2,630,000 |
| Market Cap | $281M |
| Year Range | $0.73 - $3.83 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Earnings Date | August 5 '25 |
| Industry | Drug Manufacturers |
In the news
 |
Ardelyx (NASDAQ:ARDX) versus Esperion Therapeutics (NASDAQ:ESPR) Head to Head ReviewAugust 1 - ETF Daily News |
 |
Zacks Research Has Bullish Estimate for ESPR Q1 EarningsJuly 31 - ETF Daily News |
|
Zacks Research Analysts Decrease Earnings Estimates for ESPRJuly 30 - ETF Daily News |
 |
Esperion Therapeutics (ESPR) Gets Boost from Acquisition RumorsJuly 29 - Yahoo Entertainment |
 |
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out forJuly 29 - Yahoo |
|
What is Zacks Research’s Forecast for ESPR FY2025 Earnings?July 13 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 65M | 32M | 33M | -40M | -22M | -0.206 |
| Q4 '24 | 69M | 26M | 43M | -21M | -4.9M | -0.101 |
| Q3 '24 | 52M | 17M | 34M | -30M | -14M | -0.150 |
| Q2 '24 | 74M | 16M | 58M | -62M | -48M | -0.330 |
| Q1 '24 | 138M | 10M | 128M | 61M | 75M | 0.340 |
Insider Transactions View All
| Halladay Benjamin filed to sell 474,462 shares at $1.1. July 18 '25 |
| Looker Benjamin filed to sell 399,937 shares at $1.1. July 18 '25 |
| Halladay Benjamin filed to sell 474,473 shares at $1.2. June 18 '25 |
| Looker Benjamin filed to sell 401,241 shares at $1.2. June 18 '25 |
| Koenig Sheldon L. filed to sell 1,541,488 shares at $1.1. June 18 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$167.33 0% | 47 |
 |
Eli Lilly and CompanyLLY |
$762.33 0% | 58 |
 |
PfizerPFE |
$23.49 0% | 44 |
 |
AstrazenecaAZN |
$73.95 0% | 58 |
 |
AbbVieABBV |
$195.22 0% | 49 |
Read more about Esperion Therapeutics (ESPR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Esperion Therapeutics?
The Market Cap of Esperion Therapeutics is $281M.
When does Esperion Therapeutics report earnings?
Esperion Therapeutics will report its next earnings on August 5 '25.
What is the current stock price of Esperion Therapeutics?
Currently, the price of one share of Esperion Therapeutics stock is $1.40.
How can I analyze the ESPR stock price chart for investment decisions?
The ESPR stock price chart above provides a comprehensive visual representation of Esperion Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Esperion Therapeutics shares. Our platform offers an up-to-date ESPR stock price chart, along with technical data analysis and alternative data insights.
Does ESPR offer dividends to its shareholders?
As of our latest update, Esperion Therapeutics (ESPR) does not offer dividends to its shareholders. Investors interested in Esperion Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Esperion Therapeutics?
Some of the similar stocks of Esperion Therapeutics are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.